ビタミンK2市場は2029年までに2億6,470万ドルに達すると予測され、予測期間中に13.7%のCAGRを達成する見込みです。市場の主要なプレーヤーは、Gnosis By Lesaffre(Nattopharma)(フランス)、Kappa Bioscience AS(Balchem Corp.)です。(米国)、J-オイルミルズ.(日本)、Novozymes A/S(デンマーク)、BASF SE(ドイツ)、Sungen Bioscience Co., Ltd.(中国)、Vesta Nutra(米国)、Richen(中国)、Menadiona(スペイン)、GENOFOCUS(韓国)
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.4 UNIT CONSIDERED
1.4.1 CURRENCY UNIT
1.4.2 VOLUME UNIT
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key insights from industry experts
2.1.2.3 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
2.2.1 TOP-DOWN APPROACH
2.2.2 SUPPLY-SIDE ANALYSIS
2.2.3 BOTTOM-UP APPROACH
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 LIMITATIONS AND RISK ASSESSMENT
2.6 RECESSION IMPACT ANALYSIS
2.6.1 RECESSION MACROINDICATORS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VITAMIN K2 MARKET
4.2 NORTH AMERICA: VITAMIN K2 MARKET, BY PRODUCT TYPE AND KEY COUNTRY
4.3 VITAMIN K2 MARKET: SHARE OF MAJOR REGIONAL SUBMARKETS
4.4 VITAMIN K2 MARKET, BY PRODUCT TYPE AND REGION
4.5 VITAMIN K2 MARKET, BY APPLICATION FORM
4.6 VITAMIN K2 MARKET, BY SOURCE
4.7 VITAMIN K2 MARKET, BY APPLICATION
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MACROECONOMIC INDICATORS
5.2.1 RISING GDP AND POPULATION
5.2.2 RISE IN HEALTH CONCERNS AND DISEASE INCIDENCES
5.2.3 INCREASE IN HEALTHCARE EXPENDITURE AND PREVENTIVE HEALTHCARE TRENDS
5.3 MARKET DYNAMICS
5.3.1 DRIVERS
5.3.1.1 Rising health consciousness among consumers
5.3.1.2 Growing research and development activities
5.3.2 RESTRAINTS
5.3.2.1 Inconsistency in regulatory norms
5.3.2.2 Price volatility of raw materials
5.3.3 OPPORTUNITIES
5.3.3.1 Growing demand for natural and plant-based ingredients
5.3.3.2 Rising need for personalized nutrition and customized products
5.3.3.3 Untapped applications
5.3.4 CHALLENGES
5.3.4.1 Lack of consumer awareness regarding specific health benefits of Vitamin K2
5.3.4.2 High research and development costs
6 INDUSTRY TRENDS
6.1 INTRODUCTION
6.2 SUPPLY CHAIN ANALYSIS
6.3 VALUE CHAIN ANALYSIS
6.3.1 RAW MATERIAL SOURCING
6.3.2 MANUFACTURING AND PROCESSING
6.3.3 PRODUCT FORMULATION AND DEVELOPMENT
6.3.4 QUALITY ASSURANCE AND CERTIFICATION
6.3.5 MARKETING AND DISTRIBUTION
6.4 TRADE ANALYSIS
6.4.1 EXPORT SCENARIO
6.4.2 IMPORT SCENARIO
6.4.3 HS CODE FOR VITAMIN K2 WITH PRODUCT DESCRIPTION
6.5 TECHNOLOGY ANALYSIS
6.5.1 KEY TECHNOLOGY
6.5.1.1 Fermentation technology
6.5.2 COMPLEMENTARY TECHNOLOGY
6.5.2.1 Encapsulation technology
6.5.3 ADJACENT TECHNOLOGY
6.5.3.1 Biotechnology
6.6 PRICING ANALYSIS
6.6.1 AVERAGE SELLING PRICE TREND BY PRODUCT TYPE
6.6.2 AVERAGE SELLING PRICE TREND, BY REGION
6.7 ECOSYSTEM ANALYSIS
6.7.1 DEMAND SIDE
6.7.2 SUPPLY SIDE
6.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
6.9 PATENT ANALYSIS
6.9.1 LIST OF MAJOR PATENTS
6.10 KEY CONFERENCES AND EVENTS, 2024-2025
6.11 REGULATORY LANDSCAPE
6.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.11.1.1 Regulations in North America
6.11.1.1.1 US
6.11.1.1.2 Canada
6.11.1.2 Regulations in Europe
6.11.1.3 Regulations in Asia Pacific
6.11.1.3.1 China
6.11.1.3.2 India
6.12 PORTER'S FIVE FORCES ANALYSIS
6.12.1 INTENSITY OF COMPETITIVE RIVALRY
6.12.2 BARGAINING POWER OF SUPPLIERS
6.12.3 BARGAINING POWER OF BUYERS
6.12.4 THREAT OF NEW ENTRANTS
6.12.5 THREAT OF SUBSTITUTES
6.13 KEY STAKEHOLDERS AND BUYING CRITERIA
6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
6.13.2 BUYING CRITERIA
6.14 CASE STUDY ANALYSIS
6.14.1 ESTABLISHING DISTINCT RECOMMENDED DIETARY INTAKE TO PROMOTE HEALTHIER DIETARY CHOICES
6.14.2 ENHANCING ABILITY IN NUTRACEUTICAL FORMULATIONS FOR IMPROVED QUALITY AND EFFICACY
6.15 INVESTMENT AND FUNDING SCENARIO
7 VITAMIN K2 MARKET, BY FUNCTION
7.1 INTRODUCTION
7.2 BONE AND CARDIOVASCULAR HEALTH
7.2.1 COMPREHENSIVE HEALTH BENEFITS TO DRIVE MARKET
7.3 BLOOD HEALTH AND CLOTTING
7.3.1 EFFICACY IN MANAGING CLOTTING DISORDERS TO BOOST MARKET GROWTH
7.4 ANTI-INFLAMMATORY AND IMMUNITY
7.4.1 THERAPEUTIC POTENTIAL AND IMMUNITY-SUPPORTING PROPERTIES TO SUPPORT MARKET GROWTH
7.5 OTHER FUNCTIONS
8 VITAMIN K2 MARKET, BY PRODUCT TYPE
8.1 INTRODUCTION
8.2 MK-7
8.2.1 HIGH BIOAVAILABILITY TO PROPEL MARKET GROWTH
8.3 MK-4
8.3.1 POTENTIAL BENEFITS IN BONE AND CARDIOVASCULAR HEALTH TO DRIVE MARKET GROWTH
9 VITAMIN K2 MARKET, BY APPLICATION FORM
9.1 INTRODUCTION
9.2 CAPSULES AND TABLETS
9.2.1 ABILITY TO CATER TO DIVERSE CONSUMER NEEDS AND PREFERENCES TO DRIVE MARKET
9.3 POWDER AND CRYSTALLINE
9.3.1 SURGING DEMAND FOR CUSTOMIZABLE DOSAGES AND HIGH PURITY TO PROPEL MARKET GROWTH
9.4 LIQUIDS
9.4.1 GROWING NEED FOR SUPPLEMENTS WITH ENHANCED BIOAVAILABILITY TO BOOST SEGMENT GROWTH
10 VITAMIN K2 MARKET, BY SOURCE
10.1 INTRODUCTION
10.2 NATURAL ORIGIN
10.2.1 INCREASING CONSUMER PREFERENCE FOR NON-GMO SUPPLEMENTS TO BOOST MARKET GROWTH
10.3 SYNTHETIC ORIGIN
10.3.1 LOW PRODUCTION COST TO DRIVE MARKET
11 VITAMIN K2 MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 HEALTH SUPPLEMENTS
11.2.1 INCREASED AWARENESS REGARDING ASSOCIATED HEALTH BENEFITS TO DRIVE MARKET
11.3 FUNCTIONAL FOODS AND BEVERAGES
11.3.1 GROWING DEMAND FOR FORTIFIED FUNCTIONAL FOODS TO PROPEL MARKET GROWTH
11.4 PHARMACEUTICALS
11.4.1 RISING GOVERNMENT INVESTMENTS IN DEVELOPMENT OF NEW FORMULATIONS TO DRIVE MARKET
12 VITAMIN K2 MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 NORTH AMERICA: RECESSION IMPACT ANALYSIS
12.2.2 US
12.2.2.1 Growing awareness regarding importance of preventive health measures to drive market
12.2.3 CANADA
12.2.3.1 Increasing focus on preventive healthcare and natural products to propel market
12.2.4 MEXICO
12.2.4.1 High prevalence of chronic lifestyle diseases to drive market
12.3 EUROPE
12.3.1 EUROPE: RECESSION IMPACT ANALYSIS
12.3.2 GERMANY
12.3.2.1 Rising focus on proactive healthcare to drive market
12.3.3 FRANCE
12.3.3.1 Innovative products and investments in research and development to boost market growth
12.3.4 UK
12.3.4.1 Rapidly aging population to propel market growth
12.3.5 ITALY
12.3.5.1 Evolving dietary preferences to boost market growth
12.3.6 SPAIN
12.3.6.1 Growing consumer interest in health supplements to propel drive demand
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 ASIA PACIFIC: RECESSION IMPACT ANALYSIS
12.4.2 CHINA
12.4.2.1 Surging use of digital media to disseminate healthcare information to propel market
12.4.3 JAPAN
12.4.3.1 Consumer preferences for natural healthcare solutions to boost market growth
12.4.4 INDIA
12.4.4.1 Strategic market penetration initiatives by various companies to drive market
12.4.5 AUSTRALIA AND NEW ZEALAND
12.4.5.1 Changing consumer preferences and increasing health consciousness to drive demand
12.4.6 REST OF ASIA PACIFIC
12.5 ROW
12.5.1 ROW: RECESSION IMPACT ANALYSIS
12.5.2 SOUTH AMERICA
12.5.2.1 Collaboration among key market players to drive market growth
12.5.3 MIDDLE EAST AND AFRICA
12.5.3.1 Developing regulatory landscape to propel market growth
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 MARKET SHARE ANALYSIS
13.4 COMPANY VALUATION AND FINANCIAL METRICS
13.4.1 COMPANY VALUATION
13.4.2 EV/EBITDA
13.5 BRAND/PRODUCT COMPARISON ANALYSIS
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.6.1 STARS
13.6.2 EMERGING LEADERS
13.6.3 PERVASIVE PLAYERS
13.6.4 PARTICIPANTS
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.6.5.1 Company footprint
13.6.5.2 Regional footprint
13.6.5.3 Product type footprint
13.6.5.4 Application footprint
13.7 COMPANY EVALUATION MATRIX: DISTRIBUTORS/SUPPLIERS
13.7.1 PROGRESSIVE COMPANIES
13.7.2 RESPONSIVE COMPANIES
13.7.3 DYNAMIC COMPANIES
13.7.4 STARTING BLOCKS
13.7.5 COMPETITIVE BENCHMARKING
13.7.5.1 Detailed list of key distributors/suppliers
13.7.5.2 Competitive benchmarking of key distributors/suppliers
13.8 COMPETITIVE SCENARIO AND TRENDS
13.8.1 PRODUCT LAUNCHES AND DEVELOPMENTS
13.8.2 DEALS
13.8.3 EXPANSIONS
13.8.4 OTHERS
14 COMPANY PROFILES
14.1 KEY PLAYERS (MANUFACTURERS)
14.1.1 GNOSIS BY LESAFFRE (NATTOPHARMA)
14.1.1.1 Business overview
14.1.1.2 Products/Solutions/Services offered
14.1.1.3 Recent developments
14.1.1.4 MnM view
14.1.1.4.1 Right to win
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 KAPPA BIOSCIENCE AS (BALCHEM CORP.)
14.1.2.1 Business overview
14.1.2.2 Products/Solutions/Services offered
14.1.2.3 Recent developments
14.1.2.4 MnM view
14.1.2.4.1 Right to win
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 J-OIL MILLS, INC. (PLT HEALTH SOLUTIONS, INC.) (PLT HEALTH SOLUTIONS, INC.) (JAPAN)
14.1.3.1 Business overview
14.1.3.2 Products/Solutions/Services offered
14.1.3.3 Recent developments
14.1.3.4 MnM view
14.1.3.4.1 Right to win
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 NOVOZYMES A/S, PART OF NOVONESIS GROUP
14.1.4.1 Business overview
14.1.4.2 Products/Solutions/Services offered
14.1.4.3 Recent developments
14.1.4.4 MnM view
14.1.4.4.1 Right to win
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 SUNGEN BIOSCIENCE CO., LTD
14.1.5.1 Business overview
14.1.5.2 Products/Solutions/Services offered
14.1.5.3 Recent developments
14.1.5.4 MnM view
14.1.6 VESTA NUTRA
14.1.6.1 Business overview
14.1.6.2 Products/Solutions/Services offered
14.1.6.3 Recent developments
14.1.6.4 MnM view
14.1.7 RICHEN NUTRITIONAL TECHNOLOGY CO., LTD.
14.1.7.1 Business overview
14.1.7.2 Products/Solutions/Services offered
14.1.7.3 Recent developments
14.1.7.4 MnM view
14.1.8 MENADIONA
14.1.8.1 Business overview
14.1.8.2 Products/Solutions/Services offered
14.1.8.3 Recent developments
14.1.8.4 MnM view
14.1.9 GF FERMENTECH (GENOFOCUS)
14.1.9.1 Business overview
14.1.9.2 Products/Solutions/Services offered
14.1.9.3 Recent developments
14.1.9.4 MnM view
14.1.10 ANGELYEAST CO., LTD.
14.1.10.1 Business overview
14.1.10.2 Products/Solutions/Services offered
14.1.10.3 Recent developments
14.1.10.4 MnM view
14.1.11 GENEFERM BIOTECHNOLOGY CO., LTD.
14.1.11.1 Business overview
14.1.11.2 Products/Solutions/Services offered
14.1.11.3 Recent developments
14.1.11.4 MnM view
14.1.12 NAKODA CHEMICALS LTD.
14.1.12.1 Business overview
14.1.12.2 Products/Solutions/Services offered
14.1.12.3 Recent developments
14.1.12.4 MnM view
14.1.13 HAIHANG INDUSTRY CO., LTD.
14.1.13.1 Business overview
14.1.13.2 Products/Solutions/Services offered
14.1.13.3 Recent developments
14.1.13.4 MnM view
14.1.14 CHEMICEA LIMITED
14.1.14.1 Business overview
14.1.14.2 Products/Solutions/Services offered
14.1.14.3 Recent developments
14.1.14.4 MnM view
14.1.15 KYOWA HAKKO U.S.A., INC.
14.1.15.1 Business overview
14.1.15.2 Products/Solutions/Services offered
14.1.15.3 Recent developments
14.1.15.4 MnM view
14.2 DISTRIBUTORS/SUPPLIERS
14.2.1 SEEBIO BIOTECH (SHANGHAI) CO., LTD.
14.2.2 MAGNESIA GMBH
14.2.3 FALCON TRADING INTERNATIONAL
14.2.4 ABCO INDIA
14.2.5 ATLANTIC CHEMICALS TRADING GMBH
15 ADJACENT AND RELATED MARKETS
15.1 INTRODUCTION
15.2 LIMITATIONS
15.3 DIETARY SUPPLEMENTS MARKET
15.3.1 MARKET DEFINITION
15.3.2 MARKET OVERVIEW
15.4 VITAMINS MARKET
15.4.1 MARKET DEFINITION
15.4.2 MARKET OVERVIEW
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
